SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 28, 1995
ALPHA 1 BIOMEDICALS, INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
0-15070
(Commission File Number)
52-1253406
(IRS Employer Identification Number)
Two Democracy Center
6903 Rockledge Drive
Suite 1200
Bethesda, MD 20817
(Address, including Zip Code, of principal executive offices)
Registrant's telephone number, including area code:
(301) 564-4400
Item 5. Other Events
The Press Release dated September 28, 1995 for Alpha 1
Biomedicals, Inc. attached as Exhibit 1 is incorporated by
reference.
Item 7. Exhibits
(1) Press Release, dated September 28, 1995
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
Date: September 29, 1995 ALPHA 1 BIOMEDICALS, INC.
By: /s/ R.J. Lanham
R.J. Lanham
Vice President and
Chief Financial Officer
FOR IMMEDIATE RELEASE
CONTACT:Michael L. Berman, Ph.D. R.J. Lanham
President and Vice President and
Chief Executive Officer Chief Financial Officer
301-564-4400 301-564-4400
ALPHA 1 BIOMEDICALS
SETTLES SECURITIES LITIGATION
Bethesda, Maryland, September 28, 1995 -- Alpha 1 Biomedicals,
Inc. (OTC Bulletin Board: ALBM). Michael L. Berman, Ph.D.,
President and Chief Executive Officer announced today the
settlement, subject to final court approval, of a securities
class action suit that had been filed against the Company in
connection with certain public statements concerning the product
Thymosin alpha 1. In a stipulation of settlement filed on
September 26, 1995, with the United States District Court for the
District of Maryland, the plaintiff class agreed to the dismissal
of their complaint with prejudice and release the Company from
all claims in exchange for a settlement payment of $100,000 in
cash and 500,000 shares of Alpha 1 common stock.
In March 1995, the District Court issued an order dismissing a
substantial portion of the plaintiffs' claims. In announcing the
settlement of this action, Dr. Berman stated that "the Company
continues to believe that the remaining claim is without merit."
Dr. Berman further stated that "the Company is entering into this
settlement solely to avoid the distraction and continuing costs
of this litigation and to allow the Company to focus its
attention on its future business prospects."
In September, 1994, the Company completed the licensing of the
worldwide rights to Thymosin alpha 1 to SciClone Pharmaceuticals,
Inc. Alpha 1 currently is directing its efforts towards the
development of Thymosin beta 4, a novel actin-sequestering
peptide, which could have applications in the treatment of cystic
fibrosis, sepsis, adult respiratory distress syndrome, chronic
bronchitis and asthma.
